Draft Guidance Document - Cancellation of a Drug Identification Number (DIN) and Notification of the Discontinuation of Sales

The online consultation is now closed. The final guidance is available now. Comments and suggestions received from the consultation on the draft version of the guidance were reviewed and considered in the finalization of this document.

This guidance document provides assistance in interpreting sections of the Regulations that pertain to the cancellation of a DIN and the notification of the discontinuation of the sale of a drug to Health Canada. This guideline is designed to facilitate proper compliance by the manufacturers and to enhance consistency in the application of these regulatory requirements.

How to Get Involved

This consultation is open for comment starting June 30, 2016 until September 28, 2016. Please select and read through the link below titled "consultation document". Once read please submit your comments via email, or by mail to:

Office of Submissions and Intellectual Property
Therapeutic Products Directorate
Health Products and Food Branch
Health Canada
Address Locator 0201A1
Finance Building
101 Tunney's Pasture Driveway
Ottawa, Ontario
K1A 0K9

Telephone: 613-941-7281

Consultation Document: To obtain a copy of the draft guidance document that was consulted upon, please contact the Office of Submissions and Intellectual Property.

Interested parties are encouraged to provide comments and suggestions by September 28, 2016.

Reporting to Canadians

Health Canada will make the results of this consultation available on this web site.

If you have any questions, contact us at Office of Submissions and Intellectual Property.

Interested in our other consultations? Sign up and stay informed about topics that matter to you.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: